Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Marchese, Anna ^a   Esposito, Susanna ^b   Barbieri, Ramona ^a   Bassetti, Matteo ^c   Debbia, Eugenio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antibiotics; CLSI; H. influenzae; Interpretive criteria; M. catarrhalis; Resistance; S. aureus; S. pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFOTAXIME; CEFPODOXIME; CEFUROXIME AXETIL; CLINDAMYCIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; CLINICAL PRACTICE; COMMUNICABLE DISEASE; HAEMOPHILUS INFLUENZAE; LETTER; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRACTICE GUIDELINE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; UPPER RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; GUIDELINES AS TOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 84864502238     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-181     Document Type: Letter

References (33)

1. Klugman KP. Clinical impact of antibiotic resistance in respiratory tract infections. Int J Antimicrob Agents 2007, 29(Suppl 1):S6-S10.
2. Bartlett JG. Is activity against " atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis 2008, 1;47(Suppl 3):S232-S236.
3. Esposito S, Marchisio P, Capaccio P, Bellasio M, Corti F, Dusi E, Blasi F, Pignataro L, Principi N. Role of atypical bacteria in children undergoing tonsillectomy because of severely recurrent acute tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 2008, 27:1233-1237. 10.1007/s10096-008-0560-0, 18566843.
4. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002, 35:113-125. 10.1086/340949, 12087516.
5. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26:1138-1180. 10.1183/09031936.05.00055705, 16319346.
6. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
7. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH, Moore MR, St Peter SD, Stockwell JA, Swanson JT. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011, 53:25-76.
8. European Committee on antimicrobial susceptibility testing (Eucast) website http://www.eucast.org/mic_distributions/.
9. Goldstein FW, Acar JF. Antimicrobial resistance among lower respiratory tract isolates ofStreptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. J Antimicrob Chemother 1996, 38(Suppl A):71-84. 10.1093/jac/38.suppl_A.71, 8858474.
10. Schito GC, Mannelli S, Marchese A, Cibrario-Sent M, Debbia EA. Resistenza ai farmaci antimicrobici in Streptococcus pneumoniae circolanti nel 1999 in Italia. Giorn Ital Microbiol Med Odontoiatrica Clin 2002, IV(1):13-30.
11. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement. M100-S22 2012, Wayne, PA, USA, Clinical and Laboratory Standards Institute (CLSI).
12. Clinical and Laboratory Standards Institute (CLSI) Methods for Antimicrobial Dilution and Disk Susceptibiltiy Testing of Infrequently Isolated or Fastidious Bacteria 2012, Approved Guideline M45-A2, Wayne, PA, USA, Second, Clinical and Laboratory Standards Institute (CLSI).
13. European Committee on antimicrobial susceptibility testing (Eucast) documents Document version 2.0 2012-01-01 2012, http://eucast.org/clinical_breakpoints, European Committee on antimicrobial susceptibility testing (Eucast) documents.
14. Marchese A, Schito GC. Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance?. Int J Antimicrob Agents 2007, 9(Suppl 1):S2-S5.
15. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents 2007, 30(Suppl 2):S135-S138.
16. Song JH, Chung DR. Respiratory infections due to drug-resistant bacteria. Infect Dis Clin North Am 2010, 24:639-653. 10.1016/j.idc.2010.04.007, 20674796.
17. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008, 61:621-628. 10.1093/jac/dkm536, 2952740, 18252694.
18. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Österlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003, 52:145-148. 10.1093/jac/dkg312, 12837738.
19. Kahlmeter G. EUCAST procedure for harmonizing and defining breakpoints 2012, http://www.srga.org/EUCAST/bpsetting.html.
20. Varaldo PE, Debbia EA, Nicoletti G, Pavesio D, Ripa S, Schito GC, Tempera G. Nationwide survey in Italy of treatment ofStreptococcus pyogenespharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group. Clin Infect Dis 1999, 29:869-873. 10.1086/520451, 10589905.
21. Malhotra-Kumar S, Lammens C, Chapelle C, Mallentjer C, Weyler J, Goossens H. Clonal spread of fluoroquinolone non-susceptible Streptococus pyogenes. J Antimicrob Chemother 2005, 55:320-325. 10.1093/jac/dki011, 15705642.
22. Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I. Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal. Antimicrob Agents Chemother 2010, 54:2677-2680. 10.1128/AAC.01536-09, 2876401, 20350943.
23. Arai K, Hirakata Y, Yano H, Kanamori H, Endo S, Hirotani A, Abe Y, Nagasawa M, Kitagawa M, Aoyagi T, Hatta M, Yamada M, Nishimaki K, Takayama Y, Yamamoto N, Kunishima H, Kaku M. Emergence of fluoroquinolone-resistant Streptococcus pyogenes in Japan by a point mutation leading to a new amino acid substitution. J Antimicrob Chemother 2011, 66:494-498. 10.1093/jac/dkq477, 21172783.
24. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48(11):1596-1600. 10.1086/598975, 19400744.
25. Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 2005, 41(Suppl 4):S234-S328.
26. Aebi C. Moraxella catarrhalis- pathogen or commensal?. Adv Exp Med Biol 2011, 697:107-116. 10.1007/978-1-4419-7185-2_9, 21120723.
27. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007, 20:368-389. 10.1128/CMR.00040-06, 1865592, 17428889.
28. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl 3):iii3-iii9. 3143426, 21482567.
29. Scottish Intercollegiale Guidelines network (SIGN) Diagnosis and management of childhood otitis media in primary care 2011, http://www.sign.ac.uk, Scottish Intercollegiale Guidelines network (SIGN).
30. Forgie S, Zhanel G, Robinson J. Management of acute otitis media. Paediatr Child Health 2009, 14:457-460. http://www.topalbertadoctors.org Accessed December 2011, 2786953, 20808476.
31. Brithis Columbia Acute otitis media guideline 2010, http://www.healthservices.gov.bc.ca/msp/protoguides Accessed December 2011, Brithis Columbia.
32. Marchisio P, Bellussi L, Di Mauro G, Doria M, Felisati G, Longhi R, Novelli A, Speciale A, Mansi N, Principi N. Acute otitis media: From diagnosis to prevention. Summary of the Italian guideline. Int J Pediatr Otorhinolaryngol 2010, 74:1209-1216. 10.1016/j.ijporl.2010.08.016, 20843561.
33. Institute for Clinical System Improvements Respiratory Illness in Children and Adults, Diagnosis and Treatment of (Guideline) http://www.icsi.org Accessed December 2011, Institute for Clinical System Improvements.